S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02%
Next Bullish Trade
Sign in
XNCR

Xencor, Inc. XNCR

$17.47 +2.52 (+16.86%)
Blow-off · +2.53σ Hot zone
+ Compare Open in Sniper

Price chart

Timeframe
Range
Fundamentals · free Click ▲ earnings markers (daily) for the day's move

Loading…

Latest bar · XNCR

Momentum reads · latest daily bar
Last
$17.47
+2.52 (+16.86%)
Mkt cap
$1.3B
Healthcare
RSI(14)
71.2
overbought
Stochastic %K
45.8
neutral
MFI(14)
59.1
neutral
ADX(14)
37.1
trending

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $0.0B $-0.1B $-0.1B $-0.1B -2854.7% -1724.1%
2025-12-31 $0.0B $-0.0B $-0.1B $-0.1B -23.6% -189.9%
2025-09-30 $0.0B $-0.0B $-0.0B $-0.0B -28.7% -226.3%
2025-06-30 $0.0B $-0.0B $-0.0B $-0.0B -70.7% -76.1%
2025-03-31 $0.0B $-0.0B $-0.0B $-0.0B -147.9% -131.9%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare XNCR vs peers

Line XNCR up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing XNCR no peers yet — add up to 4 below
Sector peers + LLY + UNH + JNJ + MRK + ABBV + PFE
Popular + AAPL + MSFT + NVDA + AMZN + GOOG + META + TSLA + AVGO
Matchups NVDA · AMD · AVGO · SMCI · MU AAPL · MSFT · GOOG · META · AMZN JPM · GS · MS · BAC · C TSLA · RIVN · LCID · GM · F XOM · CVX · OXY · COP

Add tickers to compare with XNCR

~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.

Earnings replay · last 0 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

No earnings history available.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
XNCR ★ $1B — -4.9 13.3 -5.1 2.0 -152.2% -86.2% — -5.94%
LLY $1,051B 41.8 26.3 14.6 30.1 33.8 82.8% 55.5% 169.9% 0.87%
UNH $387B 32.1 19.2 0.9 17.7 4.0 19.5% 0.4% 61.5% 5.88%
JNJ $609B 29.3 19.7 6.2 18.4 7.5 68.1% 6.6% -1.0% —
MRK $315B 36.0 13.2 4.8 12.1 6.9 76.7% 4.9% — 4.46%
ABBV $450B 124.8 15.6 7.2 17.2 -67.6 72.0% 12.4% -46.2% 4.63%
PFE $143B 19.1 8.8 2.3 7.6 1.6 74.8% 5.4% -10.1% 8.67%
TMO $198B 29.2 19.5 4.4 21.1 3.8 40.9% 6.2% 11.3% 2.79%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 77.91%

HolderShares% out
Blackrock Inc. 13,035,918 17.58%
Primecap Management Company 10,338,022 13.94%
BVF Inc. 7,133,720 9.62%
RTW Investments LP 6,777,461 9.14%
RA Capital Management, L.P. 4,897,237 6.61%
State Street Corporation 4,352,036 5.87%
Vanguard Portfolio Management LLC 3,500,342 4.72%
Vanguard Capital Management LLC 3,101,647 4.18%
TCG Crossover Management, LLC 2,452,138 3.31%
EcoR1 Capital, LLC 2,183,000 2.94%

Insider activity · 90d

14 buys / 1 sells · ratio 14.0 · Finnhub

  • Feigal Ellen SELL 12,340 @ $13.06
  • Deshaies Raymond Joseph BUY 20,604
  • Deshaies Raymond Joseph BUY 10,302
  • Feigal Ellen BUY 20,604
  • Feigal Ellen BUY 22,642
  • Klencke Barbara BUY 20,604
  • Klencke Barbara BUY 29,974
  • GUSTAFSON KURT A BUY 20,604
  • GUSTAFSON KURT A BUY 25,011
  • Montgomery Alan Bruce BUY 20,604

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low
$14.0
Mean
$28.33333
High
$43.0
Analysts
12
Recommendation distribution · period 2026-07-01
6
11
3
Revision trend (2026-04-01 → 2026-07-01): net 17 → 17 0 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

FormFiled DescriptionAction
4 2026-07-08 FORM 4 view ·
4 2026-07-08 FORM 4 view ·
4 2026-07-08 FORM 4 view ·
4 2026-07-08 FORM 4 view ·
4 2026-07-08 FORM 4 view ·
4 2026-07-08 FORM 4 view ·
4 2026-07-08 FORM 4 view ·
4 2026-07-08 FORM 4 view ·
4 2026-06-22 FORM 4 view ·
8-K 2026-06-18 8-K view ·
4 2026-06-17 FORM 4 view ·
4 2026-06-17 FORM 4 view ·
4 2026-06-17 FORM 4 view ·
4 2026-06-17 FORM 4 view ·
10-Q 2026-05-06 10-Q view ·
8-K 2026-05-06 8-K view ·
8-K 2026-05-05 8-K view ·
DEF 14A 2026-04-27 DEF 14A view ·
8-K 2026-04-27 8-K view ·
4 2026-04-13 FORM 4 view ·
4 2026-03-09 FORM 4 view ·
4 2026-03-09 FORM 4 view ·
4 2026-03-09 FORM 4 view ·
4 2026-03-09 FORM 4 view ·
8-K 2026-03-09 8-K view ·
4 2026-03-04 FORM 4 view ·
4 2026-03-04 FORM 4 view ·
4 2026-03-04 FORM 4 view ·
4 2026-03-04 FORM 4 view ·
8-K 2026-03-04 8-K view ·
10-K 2026-02-25 10-K view ·
8-K 2026-02-25 8-K view ·
4 2026-01-26 FORM 4 view ·
8-K 2026-01-08 8-K view ·
4 2025-12-23 FORM 4 view ·
4 2025-12-23 FORM 4 view ·
10-Q 2025-11-05 10-Q view ·
8-K 2025-11-05 8-K view ·
8-K 2025-10-24 8-K view ·
10-Q 2025-08-06 10-Q view ·
8-K 2025-08-06 8-K view ·
4 2025-07-31 FORM 4 view ·
8-K 2025-07-31 8-K view ·
4 2025-06-16 PRIMARY DOCUMENT view ·
4 2025-06-16 PRIMARY DOCUMENT view ·
4 2025-06-16 PRIMARY DOCUMENT view ·
4 2025-06-16 PRIMARY DOCUMENT view ·
4 2025-06-16 PRIMARY DOCUMENT view ·
4 2025-06-16 PRIMARY DOCUMENT view ·
4 2025-06-16 PRIMARY DOCUMENT view ·
8-K 2025-06-13 8-K view ·
10-Q 2025-05-07 10-Q view ·
8-K 2025-05-07 8-K view ·
4 2025-05-06 PRIMARY DOCUMENT view ·
8-K 2025-04-30 8-K view ·
DEF 14A 2025-04-23 DEF 14A view ·
4 2025-04-14 PRIMARY DOCUMENT view ·
4 2025-03-13 PRIMARY DOCUMENT view ·
8-K 2025-03-13 8-K view ·
4 2025-03-11 PRIMARY DOCUMENT view ·

About XNCR

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to …

Options picks · XNCR

ITM + OTM ideas from the latest scan

Loading…

Congress trades · XNCR

STOCK Act disclosures

Loading…

SEC filings & insiders · XNCR

EDGAR · live

Loading…

Holders · XNCR

Institutions & insider activity

Loading…